CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 116 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $101,325,221 | +105.8% | 3,407,035 | +24.7% | 0.00% | +100.0% |
| Q2 2023 | $49,243,867 | +13.9% | 2,732,734 | +1.5% | 0.00% | 0.0% |
| Q1 2023 | $43,250,575 | -1.0% | 2,693,062 | +12.9% | 0.00% | 0.0% |
| Q4 2022 | $43,670,882 | -5.6% | 2,386,387 | +1.3% | 0.00% | 0.0% |
| Q3 2022 | $46,284,000 | +1.5% | 2,356,647 | -3.6% | 0.00% | 0.0% |
| Q2 2022 | $45,590,000 | -1.1% | 2,444,514 | +16.4% | 0.00% | 0.0% |
| Q1 2022 | $46,079,000 | -22.6% | 2,099,313 | +0.1% | 0.00% | 0.0% |
| Q4 2021 | $59,572,000 | +68.9% | 2,096,898 | +25.1% | 0.00% | 0.0% |
| Q3 2021 | $35,277,000 | +24.5% | 1,675,881 | +11.5% | 0.00% | 0.0% |
| Q2 2021 | $28,328,000 | +59.3% | 1,502,837 | +29.1% | 0.00% | – |
| Q1 2021 | $17,785,000 | +9.4% | 1,163,917 | +1.0% | 0.00% | – |
| Q4 2020 | $16,257,000 | -4.0% | 1,152,258 | +6.6% | 0.00% | -100.0% |
| Q3 2020 | $16,940,000 | -10.6% | 1,081,098 | +0.0% | 0.00% | 0.0% |
| Q2 2020 | $18,941,000 | +153.5% | 1,081,036 | +112.7% | 0.00% | – |
| Q1 2020 | $7,471,000 | -40.9% | 508,217 | +0.8% | 0.00% | – |
| Q4 2019 | $12,646,000 | +66.8% | 504,001 | -0.0% | 0.00% | – |
| Q3 2019 | $7,583,000 | -39.9% | 504,101 | -0.1% | 0.00% | – |
| Q2 2019 | $12,614,000 | +22.6% | 504,539 | +11.6% | 0.00% | – |
| Q1 2019 | $10,292,000 | +25.8% | 452,212 | +65.8% | 0.00% | – |
| Q4 2018 | $8,179,000 | +15.1% | 272,723 | +10.0% | 0.00% | – |
| Q3 2018 | $7,103,000 | – | 247,923 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 1,875,209 | $28,203,000 | 1.68% |
| Opaleye Management Inc. | 207,000 | $3,113,000 | 1.13% |
| Perceptive Advisors | 2,587,953 | $38,922,000 | 1.05% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,121,000 | 0.64% |
| Orbimed Advisors | 2,039,282 | $30,671,000 | 0.58% |
| Eventide Asset Management | 947,000 | $14,243,000 | 0.47% |
| Novo Holdings A/S | 135,009 | $2,031,000 | 0.35% |
| Baker Brothers Advisors | 175,000 | $2,632,000 | 0.02% |
| Polar Capital LLP | 90,382 | $1,359,000 | 0.01% |
| Point72 Asset Management, L.P. | 132,000 | $1,985,000 | 0.01% |